Table 1.

GSEA on gene sets that showed enrichment in patients that showed no clinical benefit (Progressive disease [PD] + stable disease [SD] <6 months) vs. benefit (PD + SD ≥6 months) compared with gene sets enriched in Prex-resistant OVCAR5R cell line vs. parental OVCAR5.

No benefit vs. benefit	OVCAR5R vs. OVCAR5
RNA polymerase	Neuroactive ligand receptor interaction
Pyrimidine metabolism	Sphingolipid metabolism
Spliceosome	Calcium signaling pathway
DNA replication	Mismatch repair
Base excision repair	Glycosylphosphatidylinositol gpi anchor biosynthesis
Lysine degradation	Purine metabolism
Mismatch repair	Glycosaminoglycan biosynthesis heparan sulfate
Nucleotide excision repair	Dilated cardiomyopathy
One carbon pool by folate	Basal transcription actors
Valine leucine and isoleucine degradation	DNA replication
Propanoate metabolism	Hedgehog signaling pathway
RNA degradation	Pyrimidine metabolism
Butanoate metabolism	Base excision repair
Thyroid cancer	Gap junction
Systemic lupus erythematosus	Basal cell carcinoma
Proteasome	Oocyte meiosis
Cysteine and methionine metabolism	Pathogenic Escherichia coli infection
N glycan biosynthesis	Hypertrophic cardiomyopathy hcm
Vasopressin regulated water reabsorption	Tight junction
Protein export	P53 signaling pathway